| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 599990 | Colloids and Surfaces B: Biointerfaces | 2014 | 7 Pages |
•Nebivolol loaded nanoparticles exhibit uniform size with positive zeta potential.•Polymer Eudragit® RS100 has no interaction with encapsulated nebivolol.•Nebivolol-Eudragit® RS100 nanoparticles show high encapsulation efficiency.•Nanoparticles exhibit prolonged in vitro drug release with minimum burst release.
Nebivolol, a beta-blocker, has been widely used for the treatment of hypertension and cardiovascular diseases; but has drawbacks like poor solubility and bioavailability requiring frequent dosing. The present study attempts to overcome these issues through nanoparticulate delivery system using widely used carrier Eudragit® RS100. The solvent evaporation (single emulsion) technique was used for developing nanoparticles. The impact of formulation and process variables on particle size and entrapment efficiency was studied to optimize the formulation. The physico-chemical characterization confirmed the particle size in nano range with smooth and spherical morphology. Further, Fourier transforms infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) studies confirm compatibility of drug–polymer combination. The in vitro drug release study of the prepared nanoparticles showed prolongation of drug release with reduced burst release in comparison with pure drug powder.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
